Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of JSKN033 in advanced non-small cell lung cancer
CTR20253823Phase 2Active
- Sponsor
- Kanion Pharmaceutical
- Start
- Dec 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of JSKN033 in non-small cell lung cancer (NSCLC), sponsored by Kanion Pharmaceutical. Started Dec 2025; status: active.
02
Drugs
JSKN033
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20253823.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253823.